Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients
Authors:
- 30 May 2002
- journal article
- clinical trial
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 4 (3) , 177-186
Abstract
Aims/hypothesis: This study evaluated the addition of nateglinide, a d ‐phenylalanine derivative that restores early phase insulin release, to metformin in type 2 diabetes patients stabilized on high‐dose metformin. Methods: This multicentre, double‐blind, parallel group trial included 467 metformin‐treated patients with glycosylated haemoglobin (HbA 1c ) between 6.8% and 11%. Patients were randomized to add nateglinide 60 mg, 120 mg or placebo before three meals to metformin 1000 mg b.i.d. for 24 weeks. Results: HbA 1c was significantly reduced with nateglinide 60 mg and 120 mg plus metformin compared with metformin control (−0.36%, p = 0.003; −0.59%, p < 0.001 respectively). Greater benefits occurred if patients had elevated HbA 1c at baseline (−1.38% with nateglinide 120 mg in patients with HbA 1c > 9.5%). A modest fasting plasma glucose reduction was observed. Most symptoms suggestive of hypoglycaemia occurred in patients with low HbA 1c levels (≤ 8%) at baseline, although no confirmed cases of hypoglycaemia occurred with nateglinide 60 mg in this patient group. Events suggestive of hypoglycaemia were confirmed in 1.1% of cases (plasma glucose ≤ 3.3 mmol/l). Weight gain over 24 weeks was 0.9 kg with nateglinide 120 mg vs. metformin alone, and plasma lipids remained unchanged. Conclusions/interpretation: In patients stabilized on high‐dose metformin, the addition of nateglinide improved glycaemic control. The combination of these agents was well tolerated and both doses of nateglinide proved effective. The efficacy of nateglinide 60 mg and the low rate of hypoglycaemia observed at this dose make it suitable for patients close to their therapeutic target on metformin monotherapy.Keywords
This publication has 25 references indexed in Scilit:
- Comparative Tolerability of Sulphonylureas in Diabetes MellitusDrug Safety, 2000
- The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitusJournal of Clinical Investigation, 1999
- Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans.Diabetes Care, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled studyDiabetes Care, 1994
- Sulfonylureas in NIDDMDiabetes Care, 1992
- Role of Reduced Suppression of Glucose Production and Diminished Early Insulin Release in Impaired Glucose ToleranceNew England Journal of Medicine, 1992
- N-Acylphenylalanines and related compounds. A new class of oral hypoglycemic agentsJournal of Medicinal Chemistry, 1988
- Pathophysiology of Insulin Secretion in Non-insulin-dependent Diabetes MellitusDiabetes Care, 1984